Form 8-K - Current report:
SEC Accession No. 0001104659-25-056421
Filing Date
2025-06-04
Accepted
2025-06-04 16:31:03
Documents
14
Period of Report
2025-05-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517129d1_8k.htm   iXBRL 8-K 30104
2 EXHIBIT 99.7 tm2517129d1_ex99-7.htm EX-99.7 3898
  Complete submission text file 0001104659-25-056421.txt   243871

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA limn-20250529.xsd EX-101.SCH 3359
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE limn-20250529_def.xml EX-101.DEF 26585
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE limn-20250529_lab.xml EX-101.LAB 36487
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE limn-20250529_pre.xml EX-101.PRE 25209
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2517129d1_8k_htm.xml XML 5328
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42626 | Film No.: 251023578
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)